Scott Zamvil, M.D., Ph.D.
Scott S. Zamvil, M.D., Ph.D., is a clinical neurologist and immunologist at the University of California, San Francisco (UCSF) who is devoted to developing novel treatments for multiple sclerosis (MS). In his laboratory research, Dr. Zamvil investigates mechanisms involved in myelin antigen presentation and T cell activation in the MS model, experimental autoimmune encephalomyelitis (EAE). His research has shown that cholesterol-lowering statin drugs can alter antigen presentation and modulate T cell activation. Dr. Zamvil is involved in translating his research from "bench to bedside" and is the Principal Investigator for the NIH-sponsored multicenter clinical trial testing Lipitor in early MS.Dr. Zamvil received his M.D. and Ph.D. in Medical Microbiology and Immunology from Stanford University, California, where he trained in internal medicine. After completing his neurology residency at Brigham and Women's Hospital in Boston he joined the Harvard neurology faculty. In 1994 he was recipient of the National Multiple Sclerosis Society's Harry Weaver Neuroscience Scholarship. Since 1998, he has been on neurology faculty at UCSF, where he is Associate Professor of Neurology. Dr. Zamvil has joint appointments as a faculty member in the Program in Immunology and the Biomedical Sciences Graduate Program at UCSF.